- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04664829
The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells From a Mesenchymal-Like to an Epithelial-Like Phenotype
Triple-negative breast cancer (TNBC) is biologically aggressive and has limited systemic treatment options, often compounded by treatment resistance.
Cell state transitions, e.g. epithelial-to-mesenchymal transition (EMT) govern cancer cell behaviour.
The investigators hypothesize that by inducing change in cell state change, TNBC cells that have manifested taxane-resistance will be more sensitized to subsequent chemotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Elaine Lim, MD
- Phone Number: 6436 8000
- Email: elaine.lim.hsuen@singhealth.com.sg
Study Locations
-
-
-
Singapore, Singapore, 169690
- Recruiting
- National Cancer Center Singapore
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with histologically or cytologically proven metastatic TNBC
- Patients whose TNBC has progressed after prior taxane therapy in the (neo)adjuvant or metastatic setting, and have not received Capecitabine or 5-fluorouracil
- Females aged 21 years and older
- ECOG performance status 0 or 1
- Life expectancy greater than three months
- Patients have normal organ and marrow function
- Site(s) of disease amenable to serial bedside biopsies before, during and after study treatment
Exclusion Criteria:
- Previous palliative radiotherapy to potentially biopsy-able lesion
- Active symptomatic central nervous system (CNS) metastases
- Spinal cord compression not definitively treated with surgery and/or radiation
- Uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent drainage procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bexarotene and Capecitabine
|
Administered orally once a day.
Starting dosage: 200mg/m^2
Other Names:
Administered orally twice a day.
Dosage: 1000mg/m^2
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumour transcriptome by RNA sequencing
Time Frame: From time of first biopsy before the start of treatment, to disease progression, up to 2 years
|
To characterize the changes in tumour transcriptome upon treatment
|
From time of first biopsy before the start of treatment, to disease progression, up to 2 years
|
Tumour protein profile by multiplex immunohistochemistry
Time Frame: From time of first biopsy before the start of study treatment, to disease progression, up to 2 years
|
To characterize the changes in tumour protein profile upon treatment
|
From time of first biopsy before the start of study treatment, to disease progression, up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidences of treatment related adverse events
Time Frame: From time of start of study treatment, to 28 days after last dose of study treatment, up to 2 years
|
From time of start of study treatment, to 28 days after last dose of study treatment, up to 2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Elaine Lim, MD, National Cancer Centre, Singapore
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BEXMET
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Triple-Negative Breast Carcinoma
-
Karolinska University HospitalRecruitingMetastatic Triple-Negative Breast CarcinomaSweden
-
Fundacio Clinic BarcelonaSOLTI Breast Cancer Research GroupNot yet recruitingMetastatic Triple-Negative Breast CarcinomaSpain
-
OncoPep, Inc.Not yet recruitingMetastatic Triple-Negative Breast Carcinoma
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Breast Cancer Stage IV | Locally Advanced Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast CarcinomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast CarcinomaUnited States
-
Roswell Park Cancer InstituteNot yet recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma | Refractory Triple-Negative Breast CarcinomaUnited States
-
National Cancer Institute (NCI)SuspendedAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Metastatic Triple-Negative Breast CarcinomaUnited States
-
Yuan YuanGateway for Cancer Research; Agenus Inc.RecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast CarcinomaUnited States
-
OHSU Knight Cancer InstituteAstraZeneca; Oregon Health and Science UniversityRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast CarcinomaUnited States
Clinical Trials on Bexarotene
-
Ligand PharmaceuticalsCompleted
-
Eisai Inc.CompletedNon-small Cell Lung CancerCanada, United States, United Kingdom, Australia, Israel, Russian Federation, Czech Republic, France, Greece, Hungary, Poland
-
Beersheva Mental Health CenterCompleted
-
Fox Chase Cancer CenterLigand PharmaceuticalsTerminatedParapsoriasisUnited States
-
Baylor Breast Care CenterNational Cancer Institute (NCI)Completed
-
Boston UniversityLigand PharmaceuticalsCompletedCutaneous T-Cell LymphomaUnited States
-
University of Medicine and Dentistry of New JerseyLigand PharmaceuticalsCompleted
-
Georgetown UniversityDaiichi Sankyo, Inc.Terminated
-
Dartmouth-Hitchcock Medical CenterBristol-Myers Squibb; Ligand PharmaceuticalsTerminatedCarcinoma, Non-small-cell LungUnited States
-
Vanderbilt UniversityCompletedMycosis Fungoides | Sezary Syndrome | Cutaneous T-cell LymphomaUnited States